SAN FRANCISCO, CA, Hawthorne Effect, a solution for decentralizing clinical trials, has closed a $20M Series A round of funding led by Northpond Ventures.
SAN FRANCISCO, CA, Hawthorne Effect, a solution for decentralizing clinical trials, announced the closing of a $20 million Series A round of funding.
The new investment brings the company's total funding to $24 million and was led by Northpond Ventures, a leading science and technology-driven venture capital firm, with participation from SignalFire and P5 Health Ventures.
Since launching in 2015, the Hawthorne Effect solution has been used across more than 50 clinical trials, of which 99% of visits and assessments were completed within the trial window, even for the most complex of visit requirements. Hawthorne Effect is actively engaged with more than 260 clinical sites and also runs trials as a single virtual site.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about